We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Repligen Corp (RGEN) Com Stk USD0.01

Sell:$180.10 Buy:$214.22 Change: $1.70 (0.89%)
Market closed |  Prices as at close on 14 January 2022 | Switch to live prices |
Change: $1.70 (0.89%)
Market closed |  Prices as at close on 14 January 2022 | Switch to live prices |
Change: $1.70 (0.89%)
Market closed |  Prices as at close on 14 January 2022 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Repligen Corporation is a life sciences company that develops and commercializes bioprocessing technologies and systems that rises flexibility in the process of manufacturing biological drugs. The Company's bioprocessing business consist of four franchises, Filtration; Chromatography; Process Analytics; and Proteins. The Filtration products are used in process development and process scale (clinical and commercial) production. The Chromatography franchise includes products used in downstream purification, development, and manufacturing of biological drugs. The Process Analytics products allow end-users to make in-line absorbance measurements allowing for the determination of protein concentration in filtration, chromatography formulation and fill-finish applications. The Proteins franchise is represented by its Protein A affinity ligands, which are a critical component of Protein A chromatography resins used in downstream purification of virtually all mAb-based drugs on the market.

Contact details

41 Seyon St Bldg 1 Ste 100
United States
+1 (781) 4499560

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$10.69 billion
Shares in issue:
55.29 million
Life Sciences Tools & Services
United States
US dollar
NASDAQ Comb. Composite

Key personnel

  • Karen Dawes
    Independent Chairperson of the Board
  • Anthony Hunt
    President, Chief Executive Officer, Director
  • Jon Snodgres
    Chief Financial Officer
  • James Bylund
    Chief Operating Officer
  • Christine Gebski
    Senior Vice President of Filtration and Chromatography
  • Ralf Kuriyel
    Senior Vice President - Research and Development

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.